Enliven Therapeutics (NASDAQ:ELVN) Shares Down 3.8%

Enliven Therapeutics, Inc. (NASDAQ:ELVN)’s stock price fell 3.8% on Wednesday . The stock traded as low as $20.56 and last traded at $20.65. 4,941 shares traded hands during trading, a decline of 98% from the average session volume of 254,249 shares. The stock had previously closed at $21.47.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. Robert W. Baird assumed coverage on shares of Enliven Therapeutics in a research report on Tuesday, June 11th. They set an “outperform” rating and a $32.00 target price on the stock. Baird R W raised Enliven Therapeutics to a “strong-buy” rating in a research report on Tuesday, June 11th. Finally, Mizuho started coverage on shares of Enliven Therapeutics in a report on Tuesday, April 9th. They issued a “buy” rating and a $34.00 price target on the stock.

Enliven Therapeutics Stock Up 10.7 %

The firm has a 50 day moving average of $21.54 and a 200 day moving average of $17.61.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings results on Tuesday, May 14th. The company reported ($0.54) EPS for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.04. As a group, equities analysts expect that Enliven Therapeutics, Inc. will post -2.26 EPS for the current year.

Insider Transactions at Enliven Therapeutics

In related news, insider Joseph P. Lyssikatos sold 30,000 shares of the company’s stock in a transaction that occurred on Thursday, April 11th. The shares were sold at an average price of $25.04, for a total transaction of $751,200.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, insider Joseph P. Lyssikatos sold 30,000 shares of Enliven Therapeutics stock in a transaction on Thursday, April 11th. The stock was sold at an average price of $25.04, for a total value of $751,200.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Anish Patel sold 1,107 shares of the stock in a transaction dated Tuesday, May 14th. The stock was sold at an average price of $25.00, for a total value of $27,675.00. The disclosure for this sale can be found here. Insiders sold 1,284,651 shares of company stock worth $28,653,538 over the last quarter. Corporate insiders own 29.20% of the company’s stock.

Hedge Funds Weigh In On Enliven Therapeutics

A number of large investors have recently modified their holdings of ELVN. Janus Henderson Group PLC increased its holdings in Enliven Therapeutics by 74.8% during the 1st quarter. Janus Henderson Group PLC now owns 713,911 shares of the company’s stock worth $12,604,000 after acquiring an additional 305,397 shares during the period. Baker BROS. Advisors LP bought a new stake in Enliven Therapeutics during the 1st quarter worth approximately $2,020,000. Blackstone Inc. bought a new stake in Enliven Therapeutics during the 1st quarter worth approximately $443,000. EntryPoint Capital LLC bought a new stake in Enliven Therapeutics during the 1st quarter worth approximately $167,000. Finally, China Universal Asset Management Co. Ltd. bought a new stake in Enliven Therapeutics during the 4th quarter worth approximately $66,000. 95.08% of the stock is currently owned by institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.